Get the Stockscreener App
2.6394
0.38%
-0.0094
Medicus Pharma Ltd stock is traded at $2.6394, with a volume of 164.82K.
It is down -0.38% in the last 24 hours and down -40.59% over the past month.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
See More
Previous Close:
$2.63
Open:
$2.67
24h Volume:
164.82K
Relative Volume:
0.99
Market Cap:
$35.69M
Revenue:
-
Net Income/Loss:
$-11.73M
P/E Ratio:
-1.909
EPS:
-1.3826
Net Cash Flow:
$-10.37M
1W Performance:
-57.47%
1M Performance:
-40.59%
6M Performance:
-9.34%
1Y Performance:
+0.00%
1-Day Range:
$2.60
$2.75
1-Week Range:
$2.34
$6.1084
52-Week Range:
$1.80
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
2.63 | 83.13M | 0 | -11.73M | -10.37M | -1.3826 |
|
LLY
Lilly Eli Co
|
744.66 | 651.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.61 | 368.73B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.36 | 328.06B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.49 | 223.60B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.21 | 312.99B | 43.59B | 15.04B | 10.74B | 3.3766 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Medicus Pharma completes $7 million public offering - Investing.com
Medicus Pharma Secures $7 Million for Cancer Treatment Trials - TipRanks
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering - Newsfile
Medicus Pharma closes $7M public offering - Proactive financial news
Medicus Pharma prices $7 million share offering - MSN
Health Sector Experiences Mixed Fortunes As Trials And Stock Moves Shake Up Market - Finimize
Biotech Stocks Plummet As Public Offerings Shake Market - Finimize
Sector Update: Health Care - marketscreener.com
Form 424B4 Medicus Pharma Ltd. - StreetInsider
Small cap wrap: ReconAfrica, Charbone Hydrogen, Medicus Pharma.... - Proactive financial news
Medicus Pharma Prices $7 Million Public Offering; Shares Fall - marketscreener.com
Medicus Pharma unveils pricing of $7M public offering - Proactive financial news
Medicus Pharma’s (MDCX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Medicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street Zen - Defense World
Medicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment Trials - TipRanks
Medicus Pharma Secures $7M Funding to Advance Revolutionary Skin Cancer Patch Through Phase 2 Trials - Stock Titan
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering - Newsfile
Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common Shares - marketscreener.com
Medicus Pharma begins UAE cancer trial expansion – ICYMI - Proactive financial news
Medicus Pharma’s (MDCX) Buy Rating Reiterated at D. Boral Capital - Defense World
OpenAI’s $6.5B Deal With Jony Ive Hints at a Post-iPhone AI Era - The Globe and Mail
Medicus Pharma receives UAE approval to begin Phase 2 study for non-invasive BCC treatment - Proactive financial news
Small cap wrap: Nextech3D.ai, Medicus Pharma, Synchronoss, ReconAfrica... - Proactive financial news
Medicus Pharma Ltd. Gains UAE Approval for Phase 2 Basal Cell Carcinoma Study - TipRanks
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates Department of Health to Commence Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin - Malay Mail
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) - Newsfile
New Non-Invasive Skin Cancer Treatment Advances to Phase 2 in UAE After 46% Success Rate - Stock Titan
Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy - Proactive financial news
Major Shareholder Sells Off Huge Chunk of Medicus Pharma Stock! - TipRanks
This Magnificent Stock Is Up 370% From Its 2022 Low -- 2 Reasons to Buy It Now, and 1 Reason to Steer Clear - The Globe and Mail
Chart of the DayJuly Wheat - The Globe and Mail
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money - The Globe and Mail
Is Google Stock Worth Buying In 2025? - The Globe and Mail
Medicus Pharma (NASDAQ:MDCX) Price Target Raised to $27.00 at D. Boral Capital - Defense World
Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews
Medicus Pharma Ltd. SEC 10-Q Report - TradingView
Medicus Pharma price target raised to $27 from $14 at D. Boral Capital - TipRanks
Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio - Benzinga
Medicus Pharma secures $15 million funding option - MSN
Medicus Pharma stock target lifted to $27 on Antev acquisition By Investing.com - Investing.com Nigeria
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Medicus Pharma stock target lifted to $27 on Antev acquisition - Investing.com Australia
Certain Common Shares of Medicus Pharma Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2025. - marketscreener.com
Certain Options of Medicus Pharma Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2025. - marketscreener.com
Maxim Group Upgrades Medicus Pharma (CVE:MDC) to “Strong-Buy” - Defense World
Medicus Pharma to acquire Antev, advancing opportunity in prostate health solutions - Proactive financial news
Medicus Pharma to acquire Antev for $75M in share exchange transaction - MSN
Medicus Pharma signs letter of intent to buy British biotech company - The Business Journals
Medicus Pharma to acquire Antev in strategic biotech deal By Investing.com - Investing.com South Africa
Medicus Pharma to acquire Antev in strategic biotech deal - Investing.com Australia
Small cap wrap: Medicus Pharma, Arizona Gold & Silver, Plug Power... - Proactive financial news
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):